mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2021-5-18-25mrj-1192Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL INVESTIGATIONS«Экстракритериальные» антифосфолипидные антитела у пациентов с антифосфолипидным синдромом и системной красной волчанкой (предварительные данные)Extra criterial antiphospholipid antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus (preliminary data)https://orcid.org/0000-0001-5217-4932ЧельдиеваФ. А.CheldievaF. A.

115522, Москва, Каширское шоссе, 34А

125993, Москва, ул. Баррикадная, 2/1, стр. 1

34A, Kashirskoe Shosse, Moscow 115522

22/1, Barrikadnaya Street, Build. 1, Moscow 125993

https://orcid.org/0000-0003-3552-2522РешетнякТ. М.ReshetnyakT. M.

Татьяна Магомедалиевна Решетняк

115522, Москва, Каширское шоссе

125993, Москва, ул. Баррикадная, 2/1, стр. 1

134A, Kashirskoe Shosse, Moscow 115522

22/1, Barrikadnaya Street, Build. 1, Moscow 125993

t_reshetnyak@yahoo.comhttps://orcid.org/0000-0002-3246-1157ЧеркасоваМ. В.CherkasovaM. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0002-6068-3080ЛилаА. М.LilaA. M.

115522, Москва, Каширское шоссе, 34А

125993, Москва, ул. Баррикадная, 2/1, стр. 1

134A, Kashirskoe Shosse, Moscow 115522

22/1, Barrikadnaya Street, Build. 1, Moscow 125993

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; кафедра ревматологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования»РоссияV.A. Nasonova Research Institute of Rheumatology; Department of Rheumatology, Russian Medical Academy of Continuing Professional EducationRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; Кафедра ревматологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Department of Rheumatology, Russian Medical Academy of Continuing Professional EducationRussian Federation2021191020211551825Copyright © Чельдиева Ф.А., Решетняк Т.М., Черкасова М.В., Лила А.М., 20212021Чельдиева Ф.А., Решетняк Т.М., Черкасова М.В., Лила А.М.Cheldieva F.A., Reshetnyak T.M., Cherkasova M.V., Lila A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1192

Роль антифосфолипидных антител (аФЛ), не входящих в классификационные критерии, при антифосфолипидном синдроме (АФС) и системной красной волчанке (СКВ) изучена недостаточно.Цель исследования – определение частоты выявления IgG-антител к домену 1 β2-гликопротеина 1 (IgG-аβ2ГП1-D1), IgA-антител к кардиолипину (аКЛ) и IgA-антител к β2-гликопротеину 1 (IgA-аβ2ГП1) у пациентов с первичным АФС и АФС в сочетании с СКВ. Пациенты и методы. В исследование включено 63 пациента, у которых выявляли IgG/IgM-аКЛ и IgG/IgM-аβ2ГП1 методом иммуноферментного анализа (ИФА) и IgG/IgM/IgA-aКЛ, IgG/IgM/IgA-аβ2ГП1 и IgG-аβ2ГП1-D1 методом хемилюминесцентного анализа (ХМА).Результаты и обсуждение. Частота обнаружения IgG-аβ2ГП1-D1 составила 76%, IgA-aКЛ – 56%, IgA-аβ2ГП1 – 48%. Изолированной позитивности по IgA-aКЛ, IgA-аβ2ГП1, IgG-аβ2ГП1-D1 не наблюдалось. Наличие IgA-aКЛ, IgA-аβ2ГП1, IgG-аβ2ГП1-D1 ассоциировалось с высокой позитивностью по IgG/IgM-aКЛ и IgG/IgM-аβ2ГП1. Отмечалась статистически значимая связь между IgA-аКЛ/IgA-аβ2ГП1 и стандартным профилем аФЛ, а также IgG-аβ2ГП1-D1, IgG-аКЛ и IgG-аβ2ГП1.Заключение. Обнаружена высокая частота выявления IgG-аβ2ГП1-D1, IgA-aКЛ, IgA-аβ2ГП1 у пациентов с АФС. Установлена статистически значимая связь между IgA-аКЛ/IgA-аβ2ГП1 и стандартным профилем аФЛ, а также IgG-аβ2ГП1-D1 с IgG-аКЛ и IgG-аβ2ГП1.

The role of antiphospholipid antibodies (aPL), which are not included in the classification criteria, in antiphospholipid syndrome (APS) andsystemic lupus erythematosus (SLE) is not well understood.Objective: to determine the frequency of detection of IgG antibodies to domain 1 of β2-glycoprotein 1 (IgG-aβ2GP1-D1), IgA antibodiesto cardiolipin (aCL) and IgA antibodies to β2-glycoprotein 1 (IgA-a β2GP1) in patients with primary APS and APS in combination withSLE.Patients and methods. The study included 63 patients in whom IgG/IgM-aCL and IgG/IgM-aβ2GP1 were detected by enzyme-linkedimmunosorbent assay (ELISA) and IgG/IgM/IgA-aCL, IgG/IgM/IgA-aβ2GP1 and IgG-aβ2GP1-D1 by chemiluminescence analysis (CLA).Results and discussion. The detection rate of IgG-aβ2GP1-D1 was 76%, IgA-aCL – 56%, IgA-aβ2GP1 – 48%. Isolated positivity for IgA-aCL,IgA-aβ2GP1, IgG-aβ2GP1-D1 was not observed. The presence of IgA-aCL, IgA-aβ2GP1, IgG-aβ2GP1-D1 was associated with high positivity forIgG/IgM-aCL and IgG/IgM-aβ2GP1. There was a statistically significant relationship between IgA-aCL/IgA-aβ2GP1 and the standard aPLprofile, as well as IgG-aβ2GP1-D1, IgG-aCL and IgG-aβ2GP1.Conclusion. A high detection rate of IgG-aβ2GP1-D1, IgA-aCL, IgA-aβ2GP1 was found in patients with APS. A statistically significant relationshipwas found between IgA-aCL/IgA-aβ2GP1 and the standard aPL profile, as well as IgG-aβ2GP1-D1 with IgG-aCL and IgG-aβ2GP1.

антифосфолипидные антителаантифосфолипидный синдромсистемная красная волчанкаантитела к домену β2-гликопротеина 1антитела к β2-гликопротеину 1антитела к кардиолипинуantiphospholipid antibodiesantiphospholipid syndromesystemic lupus erythematosusantibodies to domain 1 of β2-glycoprotein 1antibodies to β2-glycoprotein 1antibodies to cardiolipinReferencesРешетняк ТМ. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно-практическая ревматология. 2014;52(1):56-71.Reshetnyak TM. Antiphospholipid syndrome: diagnosis and clinical manifestations (lecture). Nauchno-prakticheskaya revmatologiya. 2014;52(1):56-71. (In Russ.).Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753. xMiyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753. xНасонов ЕЛ. Антифосфолипидный синдром. Монография. Москва: Литерра; 2004. 36 с.Насонов ЕЛ. Антифосфолипидный синдром. Монография. Москва: Литерра; 2004. 36 с.Tincani A, Filippini M, Scarsi M, et al. European attempts for the standardisation of the antiphospholipid antibodies. Lupus. 2009 Sep;18(10):913-9. doi: 10.1177/0961 203309106919.Tincani A, Filippini M, Scarsi M, et al. European attempts for the standardisation of the antiphospholipid antibodies. Lupus. 2009 Sep;18(10):913-9. doi: 10.1177/0961 203309106919.Devreese KM, Pierangeli SS, de Laat B, et al. Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost. 2014 May;12(5):792-5. doi: 10.1111/jth.12537Devreese KM, Pierangeli SS, de Laat B, et al. Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost. 2014 May;12(5):792-5. doi: 10.1111/jth.12537Mahler M, Albesa R, Zohoury N, et al. Autoantibodies to domain 1 of β2 glycoprotein I determined using a novel chemilumines-cence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome. Lupus. 2016 Jul; 25(8):911-6. doi: 10.1177/0961203316640366Mahler M, Albesa R, Zohoury N, et al. Autoantibodies to domain 1 of β2 glycoprotein I determined using a novel chemilumines-cence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome. Lupus. 2016 Jul; 25(8):911-6. doi: 10.1177/0961203316640366McNeeley PA, Dlott JS, Furie RA, et al. Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I. Thromb Haemost. 2001 Aug;86(2):590-5.McNeeley PA, Dlott JS, Furie RA, et al. Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I. Thromb Haemost. 2001 Aug;86(2):590-5.De Laat B, Derksen RH, van Lummel M, et al. Pathogenic anti-beta2 glycoprotein I antibodies recognize domain I of beta-2 glycoprotein I only after a conformational change. Blood. 2006 Mar 1;107(5):1916-24. doi: 10.1182/blood-2005-05-1943De Laat B, Derksen RH, van Lummel M, et al. Pathogenic anti-beta2 glycoprotein I antibodies recognize domain I of beta-2 glycoprotein I only after a conformational change. Blood. 2006 Mar 1;107(5):1916-24. doi: 10.1182/blood-2005-05-1943Giannakopoulos B, Krillis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013 Mar 14;368(11):1033-44. doi: 10.1056/NEJMra1112830.Giannakopoulos B, Krillis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013 Mar 14;368(11):1033-44. doi: 10.1056/NEJMra1112830.Fischetti F, Durigutto P, Pellis V, et al. Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor. Blood. 2005 Oct 1;106(7):2340-6. doi: 10.1182/blood-2005-03-1319. Epub 2005 Jun 14.Fischetti F, Durigutto P, Pellis V, et al. Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor. Blood. 2005 Oct 1;106(7):2340-6. doi: 10.1182/blood-2005-03-1319. Epub 2005 Jun 14.De Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood. 2005 Feb 15;105(4):1540-5. doi: 10.1182/blood-2004-09-3387. Epub 2004 Oct 26.De Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood. 2005 Feb 15;105(4):1540-5. doi: 10.1182/blood-2004-09-3387. Epub 2004 Oct 26.Chighizola CB, Gerosa M, Meroni PL. New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies. Curr Rheumatol Rep. 2014 Feb;16(2):402. doi: 10.1007/s11926-013-0402-7Chighizola CB, Gerosa M, Meroni PL. New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies. Curr Rheumatol Rep. 2014 Feb;16(2):402. doi: 10.1007/s11926-013-0402-7Meneghel L, Ruffatti A, Gavasso S, et al. Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. Clin Chim Acta. 2015 Jun 15;446:201-5. doi: 10.1016/j.cca.2015.04.033. Epub 2015 Apr 30.Meneghel L, Ruffatti A, Gavasso S, et al. Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. Clin Chim Acta. 2015 Jun 15;446:201-5. doi: 10.1016/j.cca.2015.04.033. Epub 2015 Apr 30.De Craemer AS, Musial J, Devreese KM. Role of anti-domain 1-β2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. J Thromb Haemost. 2016 Sep;14(9):1779-87. doi: 10.1111/jth.13389De Craemer AS, Musial J, Devreese KM. Role of anti-domain 1-β2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. J Thromb Haemost. 2016 Sep;14(9):1779-87. doi: 10.1111/jth.13389Bertolaccini ML, Sanna G. The Clinical Relevance of Noncriteria Antiphospholipid Antibodies. Semin Thromb Hemost. 2018 Jul 3;44(5):453-7. doi: 10.1055/s-0037-1601328Bertolaccini ML, Sanna G. The Clinical Relevance of Noncriteria Antiphospholipid Antibodies. Semin Thromb Hemost. 2018 Jul 3;44(5):453-7. doi: 10.1055/s-0037-1601328Meijide H, Sciascia S, Sanna G, et al. The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review. Autoimmun Rev. 2013 Jan;12(3):421-5. doi: 10.1016/j.autrev.2012.08.002Meijide H, Sciascia S, Sanna G, et al. The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review. Autoimmun Rev. 2013 Jan;12(3):421-5. doi: 10.1016/j.autrev.2012.08.002Lakos G, Kiss E, Regёczy N, et al. Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol. 1999 Sep;117(3):574-9. doi: 10.1046/j.1365-2249.1999.01007.xLakos G, Kiss E, Regёczy N, et al. Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol. 1999 Sep;117(3):574-9. doi: 10.1046/j.1365-2249.1999.01007.xDiri E, Cucurull E, Gharavi AE, et al. Antiphospholipid (Hughes') syndrome in African-Americans: IgA aCL and abeta2 glycoprotein-I is the most frequent isotype. Lupus. 1999;8(4):263-8. doi: 10.1191/096120399678847812Diri E, Cucurull E, Gharavi AE, et al. Antiphospholipid (Hughes') syndrome in African-Americans: IgA aCL and abeta2 glycoprotein-I is the most frequent isotype. Lupus. 1999;8(4):263-8. doi: 10.1191/096120399678847812Liu T, Gu J, Wan L, et al. «Non-criteria» antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort. Arthritis Res Ther. 2020 Feb 21;22(1):33. doi: 10.1186/s13075-020-2131-4Liu T, Gu J, Wan L, et al. «Non-criteria» antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort. Arthritis Res Ther. 2020 Feb 21;22(1):33. doi: 10.1186/s13075-020-2131-4Martinez-Flores JA, Serrano M, Perez D, et al. Detection of circulating immune complexes of human IgA and beta 2 glycoprotein I in patients with antiphospholipid syndrome symptomatology. J Immunol Methods. 2015 Jul;422:51-8. doi: 10.1016/j.jim.2015.04.002Martinez-Flores JA, Serrano M, Perez D, et al. Detection of circulating immune complexes of human IgA and beta 2 glycoprotein I in patients with antiphospholipid syndrome symptomatology. J Immunol Methods. 2015 Jul;422:51-8. doi: 10.1016/j.jim.2015.04.002Pericleous C, Ferreira I, Borghi O, et al. Measuring IgA anti-β2-glycoprotein I and IgG/IgA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome. PLoS One. 2016 Jun 2; 11(6):e0156407. doi: 10.1371/journal.pone.0156407Pericleous C, Ferreira I, Borghi O, et al. Measuring IgA anti-β2-glycoprotein I and IgG/IgA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome. PLoS One. 2016 Jun 2; 11(6):e0156407. doi: 10.1371/journal.pone.0156407Lee RM, Branch DW, Silver RM. Immunoglobulin A anti-beta2-glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death. Am J Obstet Gynecol. 2001 Sep;185(3):748-53. doi: 10.1067/mob.2001.117659Lee RM, Branch DW, Silver RM. Immunoglobulin A anti-beta2-glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death. Am J Obstet Gynecol. 2001 Sep;185(3):748-53. doi: 10.1067/mob.2001.117659Tedesco F, Borghi MO, Gerosa M, et al. Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications. Front Immunol. 2018 Jun 19;9:1388. doi: 10.3389/fimmu.2018.01388.eCollection 2018.Tedesco F, Borghi MO, Gerosa M, et al. Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications. Front Immunol. 2018 Jun 19;9:1388. doi: 10.3389/fimmu.2018.01388.eCollection 2018.De Sousa-Pereira P, Woof JM. IgA: Structure, Function, and Developability. Antibodies (Basel). 2019 Dec 5;8(4):57. doi: 10.3390/antib8040057De Sousa-Pereira P, Woof JM. IgA: Structure, Function, and Developability. Antibodies (Basel). 2019 Dec 5;8(4):57. doi: 10.3390/antib8040057Mulla MJ, Brosens JJ, Chamley LW, et al. Antiphospholipid antibodies induce a proinflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway. Am J Reprod Immunol. 2009 Aug;62(2):96-111. doi: 10.1111/j.1600-0897.2009.00717.xMulla MJ, Brosens JJ, Chamley LW, et al. Antiphospholipid antibodies induce a proinflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway. Am J Reprod Immunol. 2009 Aug;62(2):96-111. doi: 10.1111/j.1600-0897.2009.00717.xMorales JM, Serrano M, Martinez-Flores JA, et al. Antiphospholipid Syndrome and Renal Allograft Thrombosis. Transplantation. 2019 Mar;103(3):481-6. doi: 10.1097/TP.0000000000002510Morales JM, Serrano M, Martinez-Flores JA, et al. Antiphospholipid Syndrome and Renal Allograft Thrombosis. Transplantation. 2019 Mar;103(3):481-6. doi: 10.1097/TP.0000000000002510Meroni PL, Chighizola CB, Rovelli F, Gerosa M. Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther. 2014;16(2):209. doi: 10.1186/ar4549Meroni PL, Chighizola CB, Rovelli F, Gerosa M. Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther. 2014;16(2):209. doi: 10.1186/ar4549Насонов ЕЛ, Бекетова ТВ, Решетняк ТМ и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания: на перекрестке проблем тромбовоспаления и аутоиммунитета. Научно-практическая ревматология. 2020;58(4):353-67.Nasonov EL, Beketova TV, Reshetnyak TM, et al. Coronavirus disease 2019 (COVID-19) and immuno-inflammatory rheumatic diseases: at the intersection of thromboinflammation and autoimmunity problems. Nauchno-prakticheskaya revmatologiya. 2020; 58(4):353-67. (In Russ.).Cabrera-Marante O, Rodriguez de Frias E, Serrano M, et al. The Weight of IgA Anti-β2 glycoprotein I in the Antiphospholipid Syndrome Pathogenesis: Closing the Gap of Seronegative Antiphospholipid Syndrome. Int J Mol Sci. 2020 Nov 26;21(23):8972. doi: 10.3390/ijms21238972Cabrera-Marante O, Rodriguez de Frias E, Serrano M, et al. The Weight of IgA Anti-β2 glycoprotein I in the Antiphospholipid Syndrome Pathogenesis: Closing the Gap of Seronegative Antiphospholipid Syndrome. Int J Mol Sci. 2020 Nov 26;21(23):8972. doi: 10.3390/ijms21238972Sikara MP, Routsias JG, Samiotaki M, et al.{beta}2 Glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4): Implications for the pathogenesis of antiphospholipid syndrome. Blood. 2010 Jan 21;115(3):713-23. doi: 10.1182/blood-2009-03-206367. Epub 2009 Oct 5.Sikara MP, Routsias JG, Samiotaki M, et al.{beta}2 Glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4): Implications for the pathogenesis of antiphospholipid syndrome. Blood. 2010 Jan 21;115(3):713-23. doi: 10.1182/blood-2009-03-206367. Epub 2009 Oct 5.Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020 Apr 23;382(17):e38. doi: 10.1056/NEJMc2007575.Epub 2020 Apr 8.Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020 Apr 23;382(17):e38. doi: 10.1056/NEJMc2007575.Epub 2020 Apr 8.Devreese KMJ, Linskens EA, Benoit D, Peperstraete H. Antiphospholipid antibodies in patients with COVID-19: Arelevant observation? J Thromb Haemost. 2020 Sep;18(9): 2191-201. doi: 10.1111/jth.14994. Epub 2020 Jul 23.Devreese KMJ, Linskens EA, Benoit D, Peperstraete H. Antiphospholipid antibodies in patients with COVID-19: Arelevant observation? J Thromb Haemost. 2020 Sep;18(9): 2191-201. doi: 10.1111/jth.14994. Epub 2020 Jul 23.Решетняк ТМ, Чельдиева ФА, Лила АМ, Насонов ЕЛ. Нарушения гемостаза, тромбозы, антифосфолипидные антитела у пациентов с COVID-19. Consilium Medicum. 2021;2(1):35-42.Reshetnyak TM, Chel'dieva FA, Lila AM, Nasonov EL. Hemostatic disorders, thrombosis, antiphospholipid antibodies in patients with COVID-19. Consilium Medicum. 2021; 2(1):35-42. (In Russ.).

The authors declare that there are no conflicts of interest present.